Navigation Links
SenesTech, Inc. Commences Product Registration Process With Australian Government
Date:11/10/2008

FLAGSTAFF, Ariz., Nov. 10 /PRNewswire/ -- SenesTech, Inc. has launched the regulatory process to register both the active ingredient and the first ContraPest(R) product with the government of Australia. In parallel with laboratory research and testing in the rice field rat species, registration of ContraPest(R) bait will open the door for marketing this unique rodent population management product to the agricultural ministries of Southeast Asia. ContraPest(R) will target the rice field rat, a major rodent pest species for rice agriculture in this region, known to eat or damage a significant portion of rice crops each year.

ContraPest(R) works through disruption of the reproductive potential of female rodents by selectively eliminating the female's supply of egg cells. The direct effect will be to drastically reduce the number of rats in the field. This translates to increased rice yield, and since nearly half of the world's population depends on rice for sustenance, a 10 percent increase in rice yield will feed approximately 380 million people per year. A further benefit to this humane approach to pest population control is the reduced potential for disease, since rodents and their carcasses are vectors for many human illnesses, some life-threatening.

The regulatory process for ContraPest(R) has been initiated with the Australian Pesticides and Veterinary Medicines Authority (APVMA), the Australian agency responsible for oversight of all agricultural chemical and related products that are manufactured or used in Australia. This registration process will be guided by direct consultation with regulatory expertise within the Australian government.

"The APVMA largely sets the standards for agricultural product use in Australasia, so gaining registration by the APVMA will mean nearly instantaneous acceptance of the product by governments with rice-based agriculture across the region," says Timothy L. Vail, Ph.D., Vice President of Manufacturing and Regulations for SenesTech, Inc. "Just as FDA approval is critical for pharmaceuticals in the U.S., moving ContraPest(R) through the regulatory process with the APVMA will secure our ability to manufacture the product under Australian governmental oversight using Good Manufacturing Practices. This guarantees a high standard of product quality and consistency, regardless of a particular manufacturer's location."

For additional information contact Everett Hale at ehale@senestech.com or visit http://www.senestech.com. ContraPest(R) is projected to be available for commercial use in the spring of 2010.

ABOUT: (SenesTech, Inc.) SenesTech is a platform technology company located in Flagstaff, Arizona on the Northern Arizona Center for Emerging Technology campus. SenesTech specializes in environmentally neutral fertility control products for companion animals and wildlife population control.


'/>"/>
SOURCE SenesTech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
2. Arizona-Based SenesTech, Inc., Partners With Australia to Stop Starvation Due to Rice Shortages
3. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
4. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
5. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
6. Phase 1b/2a Program Commences for RVX-208
7. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
8. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
9. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
10. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
11. Arbios Commences Process to Seek European Marketing Approval for SEPET(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , February 8, 2016 ... Oncology Private Limited, an innovation-driven oncology company developing ... and less toxic, today announced that chairman emeritus ... has invested in the company as part of ... round, joining existing investors Navam Capital and Aarin ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... a wide range of loose, bulk foods at various stages of the production ... also used to inspect large bulk products post packaging such as sacks of ...
(Date:2/8/2016)... 2016 --> ... "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces ... trachomatis (CT) test to be launched on the Company,s io® ... the CT test is now cleared for sale within the ... The launch of the io® CT test signals a new ...
(Date:2/5/2016)... SAN DIEGO , Feb. 5, 2016 ... the region,s trusted information source for community, health and ... San Diego) will integrate to enhance care coordination ... people to the services they need and to better ... to improve care.   San Diego ...
Breaking Biology Technology:
(Date:2/5/2016)... 5, 2016 http://www.researchandmarkets.com/research/5kvw8m/global_facial ... "Global Facial Recognition Market 2016-2020" ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition of ... report to their offering. --> ... has announced the addition of the ...
(Date:2/3/2016)... LIVERMORE, Calif. , Feb. 3, 2016 ... Police Department in Missouri ... of license plate reader (LPR) data from Vigilant Solutions. ... a hit-and-run case in which the victim was walking out ... a parking space next to his vehicle, striking his ...
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
Breaking Biology News(10 mins):